{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T06:43:38Z","timestamp":1791096218325,"version":"4.1.0"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2007,11,12]],"date-time":"2007-11-12T00:00:00Z","timestamp":1194825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2007,11,12]],"date-time":"2007-11-12T00:00:00Z","timestamp":1194825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1038\/sj.bmt.1705899","type":"journal-article","created":{"date-parts":[[2007,11,12]],"date-time":"2007-11-12T12:36:12Z","timestamp":1194870972000},"page":"229-237","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":102,"title":["Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies"],"prefix":"10.1038","volume":"41","author":[{"given":"V T","family":"Ho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Revta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P G","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,11,12]]},"reference":[{"key":"BF1705899_CR1","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1200\/JCO.1988.6.10.1562","volume":"6","author":"SI Bearman","year":"1988","unstructured":"Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562\u20131568.","journal-title":"J Clin Oncol"},{"key":"BF1705899_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","volume":"118","author":"GB McDonald","year":"1993","unstructured":"McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255\u2013267.","journal-title":"Ann Intern Med"},{"key":"BF1705899_CR3","first-page":"3599","volume":"92","author":"E Carreras","year":"1998","unstructured":"Carreras E, Bertz H, Arcese W, Vernant JP, Tomas JF, Hagglund H et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 1998; 92: 3599\u20133604.","journal-title":"Blood"},{"key":"BF1705899_CR4","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S1083-8791(99)70006-6","volume":"5","author":"JL Lee","year":"1999","unstructured":"Lee JL, Gooley T, Bensinger W, Schiffman K, McDonald GB . Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome. Biol Blood Marrow Transplant 1999; 5: 306\u2013315.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BF1705899_CR5","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood-2003-04-1311","volume":"103","author":"WJ Hogan","year":"2004","unstructured":"Hogan WJ, Maris M, Storer B, Sandmaier BM, Maloney DG, Schoch HG et al. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. Blood 2004; 103: 78\u201384.","journal-title":"Blood"},{"key":"BF1705899_CR6","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood.V85.11.3005.bloodjournal85113005","volume":"85","author":"SI Bearman","year":"1995","unstructured":"Bearman SI . The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995; 85: 3005\u20133020.","journal-title":"Blood"},{"key":"BF1705899_CR7","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/00007890-200211150-00018","volume":"74","author":"R Pihusch","year":"2002","unstructured":"Pihusch R, Salat C, Schmidt E, Gohring P, Pihusch M, Hiller E et al. Hemostatic complications in bone marrow transplantation: a retrospective analysis of 447 patients. Transplantation 2002; 74: 1303\u20131309.","journal-title":"Transplantation"},{"key":"BF1705899_CR8","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3109\/10428199809059219","volume":"31","author":"P Richardson","year":"1998","unstructured":"Richardson P, Bearman SI . Prevention and treatment of hepatic venocclusive disease after high-dose cytoreductive therapy. Leuk Lymphoma 1998; 31: 267\u2013277.","journal-title":"Leuk Lymphoma"},{"key":"BF1705899_CR9","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1046\/j.1365-2141.2000.02475.x","volume":"111","author":"R Chopra","year":"2000","unstructured":"Chopra R, Eaton JD, Grassi A, Potter M, Shaw B, Salat C et al. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol 2000; 111: 1122\u20131129.","journal-title":"Br J Haematol"},{"key":"BF1705899_CR10","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.1182\/blood-2002-04-1216","volume":"100","author":"PG Richardson","year":"2002","unstructured":"Richardson PG, Murakami C, Jin Z, Warren D, Momtaz P, Hoppensteadt D et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002; 100: 4337\u20134343.","journal-title":"Blood"},{"key":"BF1705899_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/sj.bmt.1704329","volume":"33","author":"S Corbacioglu","year":"2004","unstructured":"Corbacioglu S, Greil J, Peters C, Wulffraat N, Laws HJ, Dilloo D et al. Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transplant 2004; 33: 189\u2013195.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705899_CR12","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.bbmt.2004.01.002","volume":"10","author":"Y Chalandon","year":"2004","unstructured":"Chalandon Y, Roosnek E, Mermillod B, Newton A, Ozsahin H, Wacker P et al. Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2004; 10: 347\u2013354.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BF1705899_CR13","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/sj.bmt.1705485","volume":"38","author":"S Corbacioglu","year":"2006","unstructured":"Corbacioglu S, Honig M, Lahr G, Stohr S, Berry G, Friedrich W et al. Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defibrotide. Bone Marrow Transplant 2006; 38: 547\u2013553.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705899_CR14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.bmt.1705696","volume":"40","author":"F Dignan","year":"2007","unstructured":"Dignan F, Gujral D, Ethell M, Evans S, Treleaven J, Morgan G et al. Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from veno-occlusive disease. Bone Marrow Transplant 2007; 40: 79\u201382.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705899_CR15","first-page":"161A","volume":"14","author":"LD DeLeve","year":"1991","unstructured":"DeLeve LD, Kaplowitz N . Selective susceptibility of hepatic endothelial cells to dacarbazine toxicity, a model for hepatic venoocclusive disease. Hepatology 1991; 14: 161A.","journal-title":"Hepatology"},{"key":"BF1705899_CR16","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/hep.510240414","volume":"24","author":"LD DeLeve","year":"1996","unstructured":"DeLeve LD . Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation. Hepatology 1996; 24: 830\u2013837.","journal-title":"Hepatology"},{"key":"BF1705899_CR17","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/sj.bmt.1702377","volume":"25","author":"M Hassan","year":"2000","unstructured":"Hassan M, Ljungman P, Ringden O, Hassan Z, Oberg G, Nilsson C et al. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant 2000; 25: 915\u2013924.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705899_CR18","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/sj.bjc.6603097","volume":"94","author":"ME de Jonge","year":"2006","unstructured":"de Jonge ME, Huitema AD, Beijnen JH, Rodenhuis S . High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy. Br J Cancer 2006; 94: 1226\u20131230.","journal-title":"Br J Cancer"},{"key":"BF1705899_CR19","first-page":"747","volume":"14","author":"C Salat","year":"1994","unstructured":"Salat C, Holler E, Reinhardt B, Kolb HJ, Seeber B, Ledderose G et al. Parameters of the fibrinolytic system in patients undergoing BMT: elevation of PAI-1 in veno-occlusive disease. Bone Marrow Transplant 1994; 14: 747\u2013750.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705899_CR20","first-page":"458a","volume":"88","author":"P Richardson","year":"1996","unstructured":"Richardson P, Krishnan A, Wheeler C, Hoppensteadt D, Tuchin J, Fyfe H et al. Elevation of PAI-1 levels in BMT-associated VOD and changes seen with the use of defibrotide. Blood 1996; 88: 458a.","journal-title":"Blood"},{"key":"BF1705899_CR21","first-page":"219a","volume":"90","author":"P Richardson","year":"1997","unstructured":"Richardson P, Hoppensteadt D, Elias A, Frei III E, Iacobelli M, Guinan E et al. Elevation of tissue factor pathway inhibitor [TFPI], thrombomodulin [TM] and plasminogen activator inhibitor-1 [PAI-1] levels in stem cell transplant [SCT]-associated veno-occlusive disease [VOD] and changes seen with the use of defibrotide [DF]. Blood 1997; 90: 219a.","journal-title":"Blood"},{"issue":"Suppl","key":"BF1705899_CR22","first-page":"628","volume":"3185","author":"PG Richardson","year":"1999","unstructured":"Richardson PG, Hoppensteadt D, Elias AD, Kinchla N, Warren D, Iacobelli M et al. Elevation of endothelial stress products and trends seen in patients with severe veno-occlusive disease treated with defibrotide. Thromb Hemost 1999; 3185 (Suppl): 628.","journal-title":"Thromb Hemost"},{"key":"BF1705899_CR23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s002770050364","volume":"76","author":"W Nurnberger","year":"1998","unstructured":"Nurnberger W, Michelmann I, Burdach S, Gobel U . Endothelial dysfunction after bone marrow transplantation: increase of soluble thrombomodulin and PAI-1 in patients with multiple transplant-related complications. Ann Hematol 1998; 76: 61\u201365.","journal-title":"Ann Hematol"},{"key":"BF1705899_CR24","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1182\/blood.V89.6.2184","volume":"89","author":"C Salat","year":"1997","unstructured":"Salat C, Holler E, Kolbe HJ, Brigitte R, Pihusch R, Wolfgang W et al. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplant. Blood 1997; 89: 2184\u20132188.","journal-title":"Blood"},{"key":"BF1705899_CR25","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1046\/j.1365-2141.2002.03748.x","volume":"118","author":"JH Lee","year":"2002","unstructured":"Lee JH, Lee KH, Kim S, Seol M, Park CJ, Chi HS et al. Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide. Br J Haematol 2002; 118: 1087\u20131094.","journal-title":"Br J Haematol"},{"key":"BF1705899_CR26","first-page":"A13","volume":"15","author":"P Richardson","year":"1996","unstructured":"Richardson P, Krishnan A, Wheeler C, Fyfe H, Hoppensteadt D, Fareed J et al. The use of defibrotide (DF) in BMT-associated veno-occlusive disease (VOD) (Meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1996; 15: A13 1996.","journal-title":"Proc Annu Meet Am Soc Clin Oncol"},{"key":"BF1705899_CR27","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.thromres.2004.12.010","volume":"116","author":"V Pihusch","year":"2005","unstructured":"Pihusch V, Pihusch M, Penovici M, Kolb HJ, Hiller E, Pihusch R . Transforming growth factor beta-1 released from platelets contributes to hypercoagulability in veno-occlusive disease following hematopoietic stem cell transplantation. Thromb Res 2005; 116: 233\u2013240.","journal-title":"Thromb Res"},{"key":"BF1705899_CR28","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1056\/NEJM199306033282203","volume":"328","author":"MS Anscher","year":"1993","unstructured":"Anscher MS, Peters WP, Reisenbichler H, Petros WP, Jirtle RL . Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N Engl J Med 1993; 328: 1592\u20131598.","journal-title":"N Engl J Med"},{"key":"BF1705899_CR29","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/hep.1840380416","volume":"38","author":"LD DeLeve","year":"2003","unstructured":"DeLeve LD, Wang X, Kanel GC, Ito Y, Bethea NW, McCuskey MK et al. Decreased hepatic nitric oxide production contributes to the development of rat sinusoidal obstruction syndrome. Hepatology 2003; 38: 900\u2013908.","journal-title":"Hepatology"},{"key":"BF1705899_CR30","first-page":"1404","volume":"51","author":"I Kuroki","year":"2004","unstructured":"Kuroki I, Miyazaki T, Mizukami I, Matsumoto N, Matsumoto I . Effect of sodium nitroprusside on ischemia-reperfusion injuries of the rat liver. Hepatogastroenterology 2004; 51: 1404\u20131407.","journal-title":"Hepatogastroenterology"},{"key":"BF1705899_CR31","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1182\/blood-2005-07-2681","volume":"107","author":"LH Smith","year":"2006","unstructured":"Smith LH, Dixon JD, Stringham JR, Eren M, Elokdah H, Crandall DL et al. Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis. Blood 2006; 107: 132\u2013134.","journal-title":"Blood"},{"key":"BF1705899_CR32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-2002-23204","volume":"22","author":"L DeLeve","year":"2002","unstructured":"DeLeve L, Shulman HM, McDonald GB . Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002; 22: 27\u201342.","journal-title":"Semin Liver Dis"},{"key":"BF1705899_CR33","doi-asserted-by":"publisher","first-page":"589","DOI":"10.4065\/78.5.589","volume":"78","author":"S Kumar","year":"2003","unstructured":"Kumar S, DeLeve LD, Kamath PS, Tefferi A . Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation. Mayo Clin Proc 2003; 78: 589\u2013598.","journal-title":"Mayo Clin Proc"},{"key":"BF1705899_CR34","first-page":"49","volume":"3","author":"GB McDonald","year":"1993","unstructured":"McDonald GB . Venocclusive disease of the liver following marrow transplantation. Marrow Transplant Rev 1993; 3: 49\u201356.","journal-title":"Marrow Transplant Rev"},{"key":"BF1705899_CR35","first-page":"75","volume":"17","author":"C Rozman","year":"1996","unstructured":"Rozman C, Carreras E, Qian C, Gale RP, Bortin MM, Rowlings PA et al. Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia. Bone Marrow Transplant 1996; 17: 75\u201380.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705899_CR36","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0301-472X(03)00070-5","volume":"31","author":"F Moscardo","year":"2003","unstructured":"Moscardo F, Urbano-Ispizua A, Sanz GF, Brunet S, Caballero D, Vallejo C et al. Positive selection for CD34 reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. Exp Hematol 2003; 31: 545\u2013550.","journal-title":"Exp Hematol"},{"key":"BF1705899_CR37","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1200\/JCO.1991.9.7.1224","volume":"9","author":"TJ Nevill","year":"1991","unstructured":"Nevill TJ, Barnett MJ, Klingemann HG, Reece DE, Shepherd JD, Phillips GL . Regimen-related toxicity of a busulfan-cyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation. J Clin Oncol 1991; 9: 1224\u20131232.","journal-title":"J Clin Oncol"},{"key":"BF1705899_CR38","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/sj.bmt.1701225","volume":"21","author":"G Matute-Bello","year":"1998","unstructured":"Matute-Bello G, McDonald GD, Hinds MS, Schoch HG, Crawford SW . Association of pulmonary function testing abnormalities and severe veno-occlusive disease of the liver after marrow transplantation. Bone Marrow Transplant 1998; 21: 1125\u20131130.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705899_CR39","first-page":"1396","volume":"90","author":"S Cesaro","year":"2005","unstructured":"Cesaro S, Pillon M, Talenti E, Toffolutti T, Calore E, Tridello G et al. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. Haematologica 2005; 90: 1396\u20131404.","journal-title":"Haematologica"},{"key":"BF1705899_CR40","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1182\/blood.V83.9.2723.2723","volume":"83","author":"O Ringden","year":"1994","unstructured":"Ringden O, Ruutu T, Remberger M, Nikoskelainer L, Volin L, Vindelov T et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood 1994; 83: 2723\u20132730.","journal-title":"Blood"},{"key":"BF1705899_CR41","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/sj.bmt.1703047","volume":"27","author":"EA Copelan","year":"2001","unstructured":"Copelan EA, Bechtel TP, Avalos BR, Elder PJ, Ezzone SA, Scholl MD et al. Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation. Bone Marrow Transplant 2001; 27: 1121\u20131124.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705899_CR42","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1182\/blood-2002-06-1860","volume":"101","author":"GB McDonald","year":"2003","unstructured":"McDonald GB, Slattery JT, Bouvier ME, Ren S, Batchelder AL, Kalhorn TF et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003; 101: 2043\u20132048.","journal-title":"Blood"},{"key":"BF1705899_CR43","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00277-004-0982-4","volume":"84","author":"JH Lee","year":"2005","unstructured":"Lee JH, Choi SJ, Kim SE, Park CJ, Chi HS, Lee MS et al. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan+cyclophosphamide for allogeneic bone marrow transplantation. Ann Hematol 2005; 84: 321\u2013330.","journal-title":"Ann Hematol"},{"key":"BF1705899_CR44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.0902-4441.2006.t01-1-EJH2478.x","volume":"77","author":"A Clopes","year":"2006","unstructured":"Clopes A, Sureda A, Sierra J, Queralto JM, Broto A, Farre R et al. Absence of veno-occlusive disease in a cohort of multiple myeloma patients undergoing autologous stem cell transplantation with targeted busulfan dosage. Eur J Haematol 2006; 77: 1\u20136.","journal-title":"Eur J Haematol"},{"key":"BF1705899_CR45","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.bbmt.2007.03.012","volume":"13","author":"JS McCune","year":"2007","unstructured":"McCune JS, Batchelder A, Deeg HJ, Gooley T, Cole S, Phillips B et al. Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality. Biol Blood Marrow Transplant 2007; 13: 853\u2013862.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BF1705899_CR46","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1182\/blood-2003-01-0255","volume":"102","author":"M Wadleigh","year":"2003","unstructured":"Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003; 102: 1578\u20131582.","journal-title":"Blood"},{"key":"BF1705899_CR47","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2004-10-3821","volume":"106","author":"RJ Arceci","year":"2005","unstructured":"Arceci RJ, Sande J, Lange B, Shannon K, Franklin J, Hutchinson R et al. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. Blood 2005; 106: 1183\u20131188.","journal-title":"Blood"},{"key":"BF1705899_CR48","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.leukres.2006.07.005","volume":"31","author":"JM McKoy","year":"2007","unstructured":"McKoy JM, Angelotta C, Bennett CL, Tallman MS, Wadleigh M, Evens AM et al. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res 2007; 31: 599\u2013604. E-pub 7 September 2006.","journal-title":"Leuk Res"},{"key":"BF1705899_CR49","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1097\/00007890-199112000-00015","volume":"52","author":"RJ Soiffer","year":"1991","unstructured":"Soiffer RJ, Dear K, Rabinowe SN, Anderson KC, Freedman AS, Murray C et al. Hepatic dysfunction following T-cell-depleted allogeneic bone marrow transplantation. Transplantation 1991; 52: 1014\u20131019.","journal-title":"Transplantation"},{"key":"BF1705899_CR50","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/sj.bmt.1703025","volume":"27","author":"F Moscardo","year":"2001","unstructured":"Moscardo F, Sanz GF, de La Rubia J, Jimenez C, Saavedra S, Regadera A et al. Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34(+) positive selection. Bone Marrow Transplant 2001; 27: 983\u2013988.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705899_CR51","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0301-472X(03)00070-5","volume":"31","author":"F Moscardo","year":"2003","unstructured":"Moscardo F, Urbano-Ispizua A, Sanz GF, Brunet S, Caballero D, Vallejo C et al. Positive selection for CD34+ reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. Exp Hematol 2003; 31: 545\u2013550.","journal-title":"Exp Hematol"},{"key":"BF1705899_CR52","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1182\/blood-2003-02-0489","volume":"102","author":"JH Antin","year":"2003","unstructured":"Antin JH, Kim HT, Cutler C, Ho VT, Lee SJ, Miklos DB et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood 2003; 102: 1601\u20131605.","journal-title":"Blood"},{"key":"BF1705899_CR53","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.bbmt.2005.04.007","volume":"11","author":"C Cutler","year":"2005","unstructured":"Cutler C, Henry NL, Magee C, Li S, Kim HT, Alyea E et al. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 551\u2013557.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BF1705899_CR54","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood.V100.1.334","volume":"100","author":"G Eissner","year":"2002","unstructured":"Eissner G, Multhoff G, Gerbitz A, Kirchner S, Bauer S, Haffner S et al. Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide. Blood 2002; 100: 334\u2013340.","journal-title":"Blood"},{"key":"BF1705899_CR55","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0014-2999(93)90864-E","volume":"238","author":"G Bianchi","year":"1993","unstructured":"Bianchi G, Barone D, Lanzarotti E, Tettamanti R, Porta R, Moltrasio D et al. Defibrotide, a single-stranded polydeoxyribonucleotide acting as an adenosine receptor agonist. Eur J Pharmacol 1993; 238: 327\u2013334.","journal-title":"Eur J Pharmacol"},{"key":"BF1705899_CR56","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1006\/bbrc.1994.1539","volume":"200","author":"F Bracht","year":"1994","unstructured":"Bracht F, Schror K . Isolation and identification of aptamers from defibrotide that act as thrombin antagonists in vitro. Biochem Biophys Res Commun 1994; 200: 933\u2013936.","journal-title":"Biochem Biophys Res Commun"},{"key":"BF1705899_CR57","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF00609244","volume":"35","author":"S Coccheri","year":"1988","unstructured":"Coccheri S, Biagi G, Legnani C, Bianchini B, Grauso F . Acute effects of defibrotide, an experimental antithrombotic agent, on fibrinolysis and blood prostanoids in man. Eur J Clin Pharmacol 1988; 35: 151\u2013156.","journal-title":"Eur J Clin Pharmacol"},{"key":"BF1705899_CR58","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0090-6980(90)90099-H","volume":"40","author":"F Berti","year":"1990","unstructured":"Berti F, Rossoni G, Biasi G, Buschi A, Mandelli V . Defibrotide by enhancing prostacyclin generation prevents endothelin-I induced contraction in human saphenous veins. Prostaglandins 1990; 40: 337\u2013350.","journal-title":"Prostaglandins"},{"key":"BF1705899_CR59","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1055\/s-0038-1642468","volume":"71","author":"Q Zhou","year":"1994","unstructured":"Zhou Q, Chu X, Ruan C . Defibrotide stimulates expression of thrombomodulin in human endothelial cells. Thromb Hemost 1994; 71: 507\u2013510.","journal-title":"Thromb Hemost"},{"key":"BF1705899_CR60","first-page":"25","volume-title":"Advances in Vascular Pathology 1997","author":"J Fareed","year":"1997","unstructured":"Fareed J . Modulation of endothelium by heparins and defibrotide. In: Nicolaides A, Novo S (eds). Advances in Vascular Pathology 1997. Elsevier Science B.V.: Amsterdam, 1997, pp 25\u201332."},{"key":"BF1705899_CR61","first-page":"186","volume":"19","author":"ON Ulutin","year":"1993","unstructured":"Ulutin ON . Antithrombotic effect and clinical potential of defibrotide. Sem Thromb Hemost 1993; 19: 186\u2013191.","journal-title":"Sem Thromb Hemost"},{"key":"BF1705899_CR62","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0268-9499(05)80073-6","volume":"10","author":"A Jamieson","year":"1996","unstructured":"Jamieson A, Alcock P, Tuffin DP . The action of polyanionic agents defibrotide and pentosan sulphate on fibrinolytic activity in the laboratory rat. Fibrinolysis 1996; 10: 27\u201335.","journal-title":"Fibrinolysis"},{"key":"BF1705899_CR63","doi-asserted-by":"crossref","first-page":"146a","DOI":"10.1182\/blood.V94.1.146.413k39_146_155","volume":"94","author":"A Falanga","year":"1999","unstructured":"Falanga A, Marchetti M, Vignoli A, Barbui T . Defibrotide (DF) modulates tissue factor expression by microvascular endothelial cells. Blood 1999; 94: 146a.","journal-title":"Blood"},{"key":"BF1705899_CR64","doi-asserted-by":"crossref","first-page":"53a","DOI":"10.1182\/blood.V96.13.4261","volume":"96","author":"A Falanga","year":"2000","unstructured":"Falanga A, Marchetti M, Vignoli A, Barbui T . Impact of defibrotide on the fibrinolytic and procoagulant properties of endothelial cell macro- and micro-vessels. Blood 2000; 96: 53a.","journal-title":"Blood"},{"key":"BF1705899_CR65","first-page":"737","volume":"92","author":"PG Richardson","year":"1998","unstructured":"Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood 1998; 92: 737\u2013744.","journal-title":"Blood"},{"key":"BF1705899_CR66","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1182\/blood-2002-04-1216","volume":"100","author":"P Richardson","year":"2002","unstructured":"Richardson P, Murakami C, Jin Z, Warren D, Momtaz P, Hoppensteadt DA et al. Multi-institutional use of defibrotide in 88 patients post stem cell transplant with severe veno-occlusive disease and multi-system organ failure; response without significant toxicity in a high risk population and factors predictive of outcome. Blood 2002; 100: 4337\u20134343.","journal-title":"Blood"},{"key":"BF1705899_CR67","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/pbc.20934","volume":"48","author":"SR Bulley","year":"2007","unstructured":"Bulley SR, Strahm B, Doyle J, Dupuis LL . Defibrotide for the treatment of hepatic veno-occlusive disease in children. Pediatr Blood Cancer 2007; 48: 700\u2013704.","journal-title":"Pediatr Blood Cancer"},{"key":"BF1705899_CR68","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1182\/blood.V108.11.178.178","volume":"108","author":"P Richardson","year":"2006","unstructured":"Richardson P, Soiffer R, Antin J, Jin Z, Kurtzberg J, Martin P et al. Defibrotide (DF) for the treatment of severe veno-occlusive disease (sVOD) and multi-organ failure (MOF) post SCT: final results of a multi-center, randomized, dose-finding trial. Blood 2006; 108: 178.","journal-title":"Blood"},{"issue":"Suppl 1","key":"BF1705899_CR69","first-page":"51","volume":"16","author":"A Vangelista","year":"1986","unstructured":"Vangelista A, Frasca GM, Raimondi C, Liviano-D'Arcangelo G, Bonomini V . Effects of defibrotide in acute renal failure due to thrombotic microangiopathy. Haemostasis 1986; 16 (Suppl 1): 51\u201354.","journal-title":"Haemostasis"},{"key":"BF1705899_CR70","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1200\/JCO.1993.11.9.1729","volume":"11","author":"SI Bearman","year":"1993","unstructured":"Bearman SI, Anderson GL, Mori M, Hinds MS, Shulman HM, McDonald GB . Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 1993; 11: 1729\u20131736.","journal-title":"J Clin Oncol"},{"key":"BF1705899_CR71","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2003-10-3612","volume":"103","author":"B Versluys","year":"2004","unstructured":"Versluys B, Bhattacharaya R, Steward C, Cornish J, Oakhill A, Goulden N . Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure. Blood 2004; 103: 1968; letter to editor.","journal-title":"Blood"},{"key":"BF1705899_CR72","first-page":"439","volume":"5","author":"TP Baglin","year":"1990","unstructured":"Baglin TP, Harper P, Marcus RE . Veno-occlusive disease of the liver complicating ABMT successfully treated with recombinant tissue plasminogen activator (rt-PA). Bone Marrow Transplant 1990; 5: 439\u2013441.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705899_CR73","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood.V89.5.1501","volume":"89","author":"SI Bearman","year":"1997","unstructured":"Bearman SI, Lee JL, Baron AE, McDonald GB . Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood 1997; 89: 1501\u20131506.","journal-title":"Blood"},{"key":"BF1705899_CR74","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/0140-6736(92)90579-R","volume":"339","author":"JP Laporte","year":"1992","unstructured":"Laporte JP, Lesage S, Tilleul P, Najman A, Gorin NC . Alteplase for hepatic veno-occlusive disease complicating bone-marrow transplantation [letter] [see comments]. Lancet 1992; 339: 1057.","journal-title":"Lancet"},{"key":"BF1705899_CR75","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/0140-6736(92)92076-R","volume":"339","author":"G Rosti","year":"1992","unstructured":"Rosti G, Bandini G, Belardinelli A, Calori E, Tura S, Gherlinzoni F et al. Alteplase for hepatic veno-occlusive disease after bone-marrow transplantation [letter; comment] [see comments]. Lancet 1992; 339: 1481\u20131482.","journal-title":"Lancet"},{"key":"BF1705899_CR76","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/0140-6736(92)91741-P","volume":"340","author":"O Ringden","year":"1992","unstructured":"Ringden O, Wennberg L, Ericzon BG, Kallman R, Astrom M, Duraj F et al. Alteplase for hepatic veno-occlusive disease after bone marrow transplantation [letter; comment]. Lancet 1992; 340: 546\u2013547.","journal-title":"Lancet"},{"key":"BF1705899_CR77","first-page":"1101","volume":"17","author":"AM Leahey","year":"1996","unstructured":"Leahey AM, Bunin NJ . Recombinant human tissue plasminogen activator for the treatment of severe hepatic veno-occlusive disease in pediatric bone marrow transplant patients. Bone Marrow Transplant 1996; 17: 1101\u20131104.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705899_CR78","unstructured":"Feldman L, Gabai E, Milovic V, Jaimovich G . Recombinant tissue plasminogen activator (rTPA) for hepatic veno-occlusive disease after allogeneic BMT in a pediatric patient. 1995; 16: 727\u2013731."},{"key":"BF1705899_CR79","first-page":"633","volume":"18","author":"SL Goldberg","year":"1996","unstructured":"Goldberg SL, Shubert J, Rao AK, Redei I, Klumpp TR, Mangan KF . Treatment of hepatic veno-occlusive disease with low-dose tissue plasminogen activator: impact on coagulation profile. Bone Marrow Transplant 1996; 18: 633\u2013636.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705899_CR80","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/0145-2126(95)00009-D","volume":"19","author":"M Higashigawa","year":"1995","unstructured":"Higashigawa M, Watanabe M, Nishihara H, Tabata N, Azuma E, Ido M et al. Successful treatment of an infant with veno-occlusive disease developed after allogeneic bone marrow transplantation by tissue plasminogen activator, heparin and prostaglandin E1. Leuk Res 1995; 19: 477\u2013480.","journal-title":"Leuk Res"},{"key":"BF1705899_CR81","first-page":"3535","volume":"27","author":"H Hagglund","year":"1995","unstructured":"Hagglund H, Ringden O, Ljungman P . No beneficial effects, but severe side effects caused by recombinant human tissue plasminogen activator for treatment of hepatic veno-occlusive disease after allogeneic bone marrow transplantation. Transplantation 1995; 27: 3535.","journal-title":"Transplantation"},{"key":"BF1705899_CR82","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3346\/jkms.1996.11.2.118","volume":"11","author":"JH Lee","year":"1996","unstructured":"Lee JH, Lee KH, Choi JS, Zang DY, Kim SB, Kim SW et al. Veno-occlusive disease (VOD) of the liver in Korean patients following allogeneic bone marrow transplantation (BMT): efficacy of recombinant human tissue plasminogen activator (rt-PA) treatment. J Korean Med Sci 1996; 11: 118\u2013126.","journal-title":"J Korean Med Sci"},{"key":"BF1705899_CR83","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/ajh.2830460307","volume":"46","author":"LC Yu","year":"1994","unstructured":"Yu LC, Malkani I, Regueira O, Ode DL, Warrier RP . Recombinant tissue plasminogen activator (rt-PA) for veno-occlusive liver disease in pediatric autologous bone marrow transplant patients. Am J Hematol 1994; 46: 194\u2013198.","journal-title":"Am J Hematol"},{"key":"BF1705899_CR84","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/sj.bmt.1702069","volume":"24","author":"J Schriber","year":"1999","unstructured":"Schriber J, Milk B, Shaw D, Christiansen N, Baer M, Slack J et al. Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation. Bone Marrow Transplant 1999; 24: 1311\u20131314.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705899_CR85","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/sj.bmt.1701654","volume":"23","author":"S Kulkarni","year":"1999","unstructured":"Kulkarni S, Rodriguez M, Lafuente A, Mateos P, Mehta J, Singhal S et al. Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno-occlusive disease (VOD). Bone Marrow Transplant 1999; 23: 803\u2013807.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705899_CR86","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/sj.bmt.1700985","volume":"20","author":"JD Morris","year":"1997","unstructured":"Morris JD, Harris RE, Hashmi R, Sambrano JE, Gruppo RA, Becker AT et al. Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation. Bone Marrow Transplant 1997; 20: 871\u2013878.","journal-title":"Bone Marrow Transplant"},{"issue":"Suppl 3","key":"BF1705899_CR87","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1007\/PL00014344","volume":"158","author":"R Mertens","year":"1999","unstructured":"Mertens R, Brost H, Granzen B, Nowak-Gottl U . Antithrombin treatment of severe hepatic veno-occlusive disease in children with cancer. Eur J Pediatr 1999; 158 (Suppl 3): S154\u2013S158.","journal-title":"Eur J Pediatr"},{"key":"BF1705899_CR88","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1345\/aph.1D235","volume":"38","author":"RB Ibrahim","year":"2004","unstructured":"Ibrahim RB, Peres E, Dansey R, Abidi MH, Abella EM, Klein J . Anti-thrombin III in the management of hematopoietic stem-cell transplantation-associated toxicity. Ann Pharmacother 2004; 38: 1053\u20131059.","journal-title":"Ann Pharmacother"},{"key":"BF1705899_CR89","first-page":"795","volume":"91","author":"U Haussmann","year":"2006","unstructured":"Haussmann U, Fischer J, Eber S, Scherer F, Seger R, Gungor T . Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III\/defibrotide therapy. Haematologica 2006; 91: 795\u2013800.","journal-title":"Haematologica"},{"key":"BF1705899_CR90","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1182\/blood.V73.5.1213.1213","volume":"73","author":"DE Vaughan","year":"1989","unstructured":"Vaughan DE, Plavin SR, Schafer AI, Loscalzo J . PGE1 accelerates thrombolysis by tissue plasminogen activator. Blood 1989; 73: 1213\u20131217.","journal-title":"Blood"},{"key":"BF1705899_CR91","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s002770050358","volume":"76","author":"PG Schlegel","year":"1998","unstructured":"Schlegel PG, Haber HP, Beck J, Krumpelmann S, Handgretinger R, Bader P et al. Hepatic veno-occlusive disease in pediatric stem cell recipients: successful treatment with continuous infusion of prostaglandin E1 and low-dose heparin. Ann Hematol 1998; 76: 37\u201341.","journal-title":"Ann Hematol"},{"key":"BF1705899_CR92","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/j.1365-2141.1993.tb03152.x","volume":"84","author":"SI Bearman","year":"1993","unstructured":"Bearman SI, Shen DD, Hinds MS, Hill HA, McDonald GB . A phase I\/II study of prostaglandin E1 for the prevention of hepatic venocclusive disease after bone marrow transplantation. Br J Haematol 1993; 84: 724\u2013730.","journal-title":"Br J Haematol"},{"key":"BF1705899_CR93","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1182\/blood.V79.11.2834.bloodjournal79112834","volume":"79","author":"M Attal","year":"1992","unstructured":"Attal M, Huguet F, Rubie H, Huynh A, Charlet JP, Payen JL et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood 1992; 79: 2834\u20132840.","journal-title":"Blood"},{"key":"BF1705899_CR94","first-page":"407","volume":"5","author":"SI Bearman","year":"1990","unstructured":"Bearman SI, Hinds MS, Wolford JL, Petersen FB, Nugent DL, Slichter SJ et al. A pilot study of continuous infusion heparin for the prevention of hepatic veno-occlusive disease after bone marrow transplantation. Bone Marrow Transplant 1990; 5: 407\u2013411.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705899_CR95","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1600-0609.1991.tb01859.x","volume":"47","author":"L Marsa-Vila","year":"1991","unstructured":"Marsa-Vila L, Gorin NC, Laporte JP . Prophylactic heparin does not prevent liver veno-occlusive disease following autologous bone marrow transplantation. Eur J Haematol 1991; 47: 346\u2013352.","journal-title":"Eur J Haematol"},{"key":"BF1705899_CR96","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1097\/00007890-199604150-00014","volume":"61","author":"R Or","year":"1996","unstructured":"Or R, Nagler A, Shpilberg O, Elad S, Naparstek E, Kapelushnik J et al. Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients. Transplantation 1996; 61: 1067\u20131071.","journal-title":"Transplantation"},{"key":"BF1705899_CR97","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/sj.bmt.1702854","volume":"27","author":"M Simon","year":"2001","unstructured":"Simon M, Hahn T, Ford LA, Anderson B, Swinnich D, Baer MR et al. Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin. Bone Marrow Transplant 2001; 27: 627\u2013633.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705899_CR98","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/sj.bmt.1703342","volume":"29","author":"SH Park","year":"2002","unstructured":"Park SH, Lee MH, Lee H, Kim HS, Kim K, Kim WS et al. A randomized trial of heparin plus ursodiol vs heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29: 137\u2013143.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705899_CR99","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/sj.bmt.1704087","volume":"31","author":"DL Forrest","year":"2003","unstructured":"Forrest DL, Thompson K, Dorcas VG, Couban SH, Pierce R . Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study. Bone Marrow Transplant 2003; 31: 1143\u20131149.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705899_CR100","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/sj.bmt.1704087","volume":"31","author":"DL Forrest","year":"2003","unstructured":"Forrest DL, Thompson K, Dorcas VG, Couban SH, Pierce R . Low molecular weight heparin for the prevention of veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study. Bone Marrow Transplant 2003; 31: 1143\u20131149.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705899_CR101","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/(SICI)1096-8652(200005)64:1<32::AID-AJH6>3.0.CO;2-N","volume":"64","author":"K Ohashi","year":"2000","unstructured":"Ohashi K, Tanabe J, Watanabe R, Tanaka T, Sakamaki H, Maruta A et al. The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation. Am J Hematol 2000; 64: 32\u201338.","journal-title":"Am J Hematol"},{"key":"BF1705899_CR102","first-page":"367","volume":"10","author":"JH Essell","year":"1992","unstructured":"Essell JH, Thompson JM, Harman GS, Halvorson RD, Snyder MJ, Callander NS et al. Pilot trial of prophylactic ursodiol to decrease the incidence of veno-occlusive disease of the liver in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1992; 10: 367\u2013372.","journal-title":"Bone Marrow Transplant"},{"issue":"12 Part 1","key":"BF1705899_CR103","doi-asserted-by":"crossref","first-page":"975","DOI":"10.7326\/0003-4819-128-12_Part_1-199806150-00002","volume":"128","author":"JH Essell","year":"1998","unstructured":"Essell JH, Schroeder MT, Harman GS, Halvorson R, Lew V, Callander N et al. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128 (12 Part 1): 975\u2013981.","journal-title":"Ann Intern Med"},{"key":"BF1705899_CR104","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1182\/blood-2001-12-0159","volume":"100","author":"T Ruutu","year":"2002","unstructured":"Ruutu T, Eriksson B, Remes K, Juvonen E, Volin L, Remberger M et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002; 100: 1977\u20131983.","journal-title":"Blood"},{"key":"BF1705899_CR105","first-page":"473","volume":"16","author":"HJ Schlitt","year":"1995","unstructured":"Schlitt HJ, Tischler HJ, Ringe B, Raddatz G, Maschek H, Dietrich H et al. Allogeneic liver transplantation for hepatic veno-occlusive disease after bone marrow transplantation\u2014clinical and immunological considerations. Bone Marrow Transplant 1995; 16: 473\u2013478.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705899_CR106","first-page":"643","volume":"18","author":"FO Smith","year":"1996","unstructured":"Smith FO, Johnson MS, Scherer LR et al. Transjugular intrahepatic portosystemic shunting (TIPS) for the treatment of severe hepatic veno-occlusive disease. Bone Marrow Transplant 1996; 18: 643\u2013646.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705899_CR107","first-page":"177","volume":"23","author":"R Alvarez","year":"2000","unstructured":"Alvarez R, Banares R, Casariego J, Echenagusia A, Simo G, Alvarez E et al. Percutaneous intrahepatic portosystemic shunting in the treatment of veno-occlusive disease of the liver after bone marrow transplantation. Gastroenterol Hepatol 2000; 23: 177\u2013180.","journal-title":"Gastroenterol Hepatol"},{"key":"BF1705899_CR108","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/sj.bmt.1703267","volume":"28","author":"A Tefferi","year":"2001","unstructured":"Tefferi A, Kumar S, Wolf RC, Lacy MQ, Inwards DJ, Gloor JM et al. Charcoal hemofiltration for hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 28: 997\u2013999.","journal-title":"Bone Marrow Transplant"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1705899.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1705899","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1705899.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:40:34Z","timestamp":1648082434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1705899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11,12]]},"references-count":108,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["BF1705899"],"URL":"https:\/\/doi.org\/10.1038\/sj.bmt.1705899","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11,12]]},"assertion":[{"value":"20 September 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2007","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}